The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 ...

In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German ...

FRANKFURT, May 5 (Reuters) - BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 ...

German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, ...

BioNTech is planning site closures affecting up to 1,860 jobs and will buy back $1 billion in shares after announcing the ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American ...

BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its ...

BioNTech shares sank yesterday as disappointing Q1 results prompted layoffs. But long-term investors still have ample reasons ...

Germany s BioNTech said Tuesday it will halt operations at several sites, in a move affecting up to 1,860 jobs, as sales of ...

The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...